1.The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
Min Cheol HAN ; Seo Hee CHOI ; Chae-Seon HONG ; Yong Bae KIM ; Woong Sub KOOM ; Jin Sung KIM ; Jaeho CHO ; Chan Woo WEE ; Changhwan KIM ; Jong Won PARK ; Soorim HAN ; Heejeong LEE ; Hong In YOON ; Ik Jae LEE ; Ki Chang KEUM
Radiation Oncology Journal 2024;42(4):295-307
Purpose:
This report offers a detailed examination of the inception and current state of the Heavy-ion Therapy Center (HITC) at the Yonsei Cancer Center (YCC), setting it apart as the world’s first center equipped with a fixed beam and two superconducting gantries for carbon-ion radiation therapy (CIRT).
Materials and Methods:
Preparations for CIRT at YCC began in 2013; accordingly, this center has completed a decade of meticulous planning and culminating since the operational commencement of the HITC in April 2023.
Results:
This report elaborates on the clinical preparation for adopting CIRT in Korea. It includes an extensive description of HITC’s facility layout at YCC, which comprises the accelerator and treatment rooms. Furthermore, this report delineates the clinical workflow, criteria for CIRT application, and the rigorous quality assurance processes implemented at YCC. It highlights YCC’s sophisticated radiation therapy infrastructure, collaborative initiatives, and the efficacious treatment of >200 prostate cancer cases utilizing CIRT.
Conclusion
This manuscript concludes by discussing the prospective influence of CIRT on the medical domain within Korea, spotlighting YCC’s pioneering contribution and forecasting the widespread integration of this groundbreaking technology.
2.The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
Min Cheol HAN ; Seo Hee CHOI ; Chae-Seon HONG ; Yong Bae KIM ; Woong Sub KOOM ; Jin Sung KIM ; Jaeho CHO ; Chan Woo WEE ; Changhwan KIM ; Jong Won PARK ; Soorim HAN ; Heejeong LEE ; Hong In YOON ; Ik Jae LEE ; Ki Chang KEUM
Radiation Oncology Journal 2024;42(4):295-307
Purpose:
This report offers a detailed examination of the inception and current state of the Heavy-ion Therapy Center (HITC) at the Yonsei Cancer Center (YCC), setting it apart as the world’s first center equipped with a fixed beam and two superconducting gantries for carbon-ion radiation therapy (CIRT).
Materials and Methods:
Preparations for CIRT at YCC began in 2013; accordingly, this center has completed a decade of meticulous planning and culminating since the operational commencement of the HITC in April 2023.
Results:
This report elaborates on the clinical preparation for adopting CIRT in Korea. It includes an extensive description of HITC’s facility layout at YCC, which comprises the accelerator and treatment rooms. Furthermore, this report delineates the clinical workflow, criteria for CIRT application, and the rigorous quality assurance processes implemented at YCC. It highlights YCC’s sophisticated radiation therapy infrastructure, collaborative initiatives, and the efficacious treatment of >200 prostate cancer cases utilizing CIRT.
Conclusion
This manuscript concludes by discussing the prospective influence of CIRT on the medical domain within Korea, spotlighting YCC’s pioneering contribution and forecasting the widespread integration of this groundbreaking technology.
3.The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
Min Cheol HAN ; Seo Hee CHOI ; Chae-Seon HONG ; Yong Bae KIM ; Woong Sub KOOM ; Jin Sung KIM ; Jaeho CHO ; Chan Woo WEE ; Changhwan KIM ; Jong Won PARK ; Soorim HAN ; Heejeong LEE ; Hong In YOON ; Ik Jae LEE ; Ki Chang KEUM
Radiation Oncology Journal 2024;42(4):295-307
Purpose:
This report offers a detailed examination of the inception and current state of the Heavy-ion Therapy Center (HITC) at the Yonsei Cancer Center (YCC), setting it apart as the world’s first center equipped with a fixed beam and two superconducting gantries for carbon-ion radiation therapy (CIRT).
Materials and Methods:
Preparations for CIRT at YCC began in 2013; accordingly, this center has completed a decade of meticulous planning and culminating since the operational commencement of the HITC in April 2023.
Results:
This report elaborates on the clinical preparation for adopting CIRT in Korea. It includes an extensive description of HITC’s facility layout at YCC, which comprises the accelerator and treatment rooms. Furthermore, this report delineates the clinical workflow, criteria for CIRT application, and the rigorous quality assurance processes implemented at YCC. It highlights YCC’s sophisticated radiation therapy infrastructure, collaborative initiatives, and the efficacious treatment of >200 prostate cancer cases utilizing CIRT.
Conclusion
This manuscript concludes by discussing the prospective influence of CIRT on the medical domain within Korea, spotlighting YCC’s pioneering contribution and forecasting the widespread integration of this groundbreaking technology.
4.The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
Min Cheol HAN ; Seo Hee CHOI ; Chae-Seon HONG ; Yong Bae KIM ; Woong Sub KOOM ; Jin Sung KIM ; Jaeho CHO ; Chan Woo WEE ; Changhwan KIM ; Jong Won PARK ; Soorim HAN ; Heejeong LEE ; Hong In YOON ; Ik Jae LEE ; Ki Chang KEUM
Radiation Oncology Journal 2024;42(4):295-307
Purpose:
This report offers a detailed examination of the inception and current state of the Heavy-ion Therapy Center (HITC) at the Yonsei Cancer Center (YCC), setting it apart as the world’s first center equipped with a fixed beam and two superconducting gantries for carbon-ion radiation therapy (CIRT).
Materials and Methods:
Preparations for CIRT at YCC began in 2013; accordingly, this center has completed a decade of meticulous planning and culminating since the operational commencement of the HITC in April 2023.
Results:
This report elaborates on the clinical preparation for adopting CIRT in Korea. It includes an extensive description of HITC’s facility layout at YCC, which comprises the accelerator and treatment rooms. Furthermore, this report delineates the clinical workflow, criteria for CIRT application, and the rigorous quality assurance processes implemented at YCC. It highlights YCC’s sophisticated radiation therapy infrastructure, collaborative initiatives, and the efficacious treatment of >200 prostate cancer cases utilizing CIRT.
Conclusion
This manuscript concludes by discussing the prospective influence of CIRT on the medical domain within Korea, spotlighting YCC’s pioneering contribution and forecasting the widespread integration of this groundbreaking technology.
5.The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
Min Cheol HAN ; Seo Hee CHOI ; Chae-Seon HONG ; Yong Bae KIM ; Woong Sub KOOM ; Jin Sung KIM ; Jaeho CHO ; Chan Woo WEE ; Changhwan KIM ; Jong Won PARK ; Soorim HAN ; Heejeong LEE ; Hong In YOON ; Ik Jae LEE ; Ki Chang KEUM
Radiation Oncology Journal 2024;42(4):295-307
Purpose:
This report offers a detailed examination of the inception and current state of the Heavy-ion Therapy Center (HITC) at the Yonsei Cancer Center (YCC), setting it apart as the world’s first center equipped with a fixed beam and two superconducting gantries for carbon-ion radiation therapy (CIRT).
Materials and Methods:
Preparations for CIRT at YCC began in 2013; accordingly, this center has completed a decade of meticulous planning and culminating since the operational commencement of the HITC in April 2023.
Results:
This report elaborates on the clinical preparation for adopting CIRT in Korea. It includes an extensive description of HITC’s facility layout at YCC, which comprises the accelerator and treatment rooms. Furthermore, this report delineates the clinical workflow, criteria for CIRT application, and the rigorous quality assurance processes implemented at YCC. It highlights YCC’s sophisticated radiation therapy infrastructure, collaborative initiatives, and the efficacious treatment of >200 prostate cancer cases utilizing CIRT.
Conclusion
This manuscript concludes by discussing the prospective influence of CIRT on the medical domain within Korea, spotlighting YCC’s pioneering contribution and forecasting the widespread integration of this groundbreaking technology.
6.Trends and an Online Survey on the Use of Rigid Bronchoscopy in Korea
Byeong-Ho JEONG ; Sang Haak LEE ; Hwan Hee KIM ; Ho Il YOON ; Jung Seop EOM ; Young Sik PARK ; Jaeyoung CHO ; Taehoon LEE ; Seung Joon KIM ; Hyeong Jun CHO ; Chan Kwon PARK ; Yousang KO ; Yong-Soo KWON ; Changhwan KIM ; Wonjun JI ; Chang-Min CHOI ; Ki-Hyun SEO ; Hae-Seong NAM ; Hojoong KIM
Journal of Korean Medical Science 2023;38(3):e13-
Background:
Although almost all interventional pulmonologists agree that rigid bronchoscopy is irreplaceable in the field of interventional pulmonology, less is known about the types of diseases that the procedure is used for and what difficulties the operators face during the procedure. The purpose of this study is to evaluate what diseases rigid bronchoscopy is used for, whether it is widely used, and what challenges the operators face in Korea.
Methods:
We enrolled 14 hospitals in this retrospective cohort of patients who underwent rigid bronchoscopy between 2003 and 2020. An online survey was conducted with 14 operators to investigate the difficulties associated with the procedure.
Results:
While the number of new patients at Samsung Medical Center (SMC) increased from 189 in 2003–2005 to 468 in 2018–2020, that of other institutions increased from 0 to 238.The proportion of SMC patients in the total started at 100% and steadily decreased to 59.2%.The proportion of malignancy as the indication for the procedure steadily increased from 29.1% to 43.0%, whereas post-tuberculous stenosis (25.4% to 12.9%) and post-intubation stenosis (19.0% to 10.9%) steadily decreased (all P for trends < 0.001). In the online survey, half of the respondents stated that over the past year they performed less than one procedure per month. The fewer the procedures performed within the last year, the more likely collaboration with other departments was viewed as a recent obstacle (Spearman correlation coefficient, r s = −0.740, P = 0.003) and recent administrative difficulties were encountered (r s = −0.616, P = 0.019).
Conclusion
This study demonstrated that the number of patients undergoing rigid bronchoscopy has been increasing, especially among cancer patients. For this procedure to be used more widely, it will be important for beginners to systematically learn about the procedure itself as well as to achieve multidisciplinary consultation.
7.Uric Acid and Risk of Cardiovascular Disease and Mortality: A Longitudinal Cohort Study
Jae Young KIM ; Changhwan SEO ; Haeyong PAK ; Hyunsun LIM ; Tae Ik CHANG
Journal of Korean Medical Science 2023;38(38):e302-
Background:
This study aimed to examine the association of serum uric acid levels with incident cardiovascular disease and mortality in Korean adults without gout.
Methods:
This large longitudinal cohort study included adults aged > 19 years who had serum uric acid levels measured at least once at the National Health Insurance Service Ilsan Hospital from January 1, 2006 to December 31, 2015. Longitudinal data on person-level cardiovascular disease and cardiovascular mortality were linked to the National Health Insurance Service claims database and National Death Index.
Results:
Among a total of 92,454 study participants with a median follow-up of 4.7 years, 7,670 (8.3%) composite events of cardiovascular disease or cardiovascular mortality were observed. Multivariable Cox proportional-hazards models revealed that each 1 mg/dL increment in uric acid level was associated with a 6% higher risk of composite outcomes.Compared with that for the uric acid level category of 4.0 to < 5.0 mg/dL, adjusted hazard ratios (95% confidence interval) for uric acid level categories of 5.0 to < 6.0, 6.0 to < 7.0, and ≥ 7.0 mg/dL were 1.10 (1.04–1.18), 1.20 (1.11–1.30), and 1.36 (1.25–1.47), respectively. In the secondary analyses for cardiovascular disease or cardiovascular mortality examined separately, a higher uric acid level was similarly associated with a higher risk of each adverse outcome. These associations were generally consistent across clinically relevant subgroups.
Conclusion
A graded association was noted between serum uric acid levels and cardiovascular risk, suggesting that higher uric acid levels may adversely affect cardiovascular health and survival in individuals without gout.
8.Fighting the COVID-19 pandemic:onsite mass workplace testing for COVID-19 in the Republic of Korea
Eunhye SEO ; Eunchan MUN ; Wonsool KIM ; Changhwan LEE
Annals of Occupational and Environmental Medicine 2020;32(1):e23-
The ongoing coronavirus disease 2019 (COVID-19) pandemic is causing tremendous damage globally. The Republic of Korea (ROK), a highly export-dependent nation, is a leader in the fight against the COVID-19 pandemic and coping well with the disaster. Like the drivethrough COVID-19 testing, which reflects the brilliant flexibility of the Korean medical system, onsite mass workplace testing for COVID-19, which our hospital has been performing over the past few months, is a unique and valuable countermeasure. We believe it is time that the current health examination system for workers in the ROK considered the risk of transmissible diseases.
9.Fighting the COVID-19 pandemic:onsite mass workplace testing for COVID-19 in the Republic of Korea
Eunhye SEO ; Eunchan MUN ; Wonsool KIM ; Changhwan LEE
Annals of Occupational and Environmental Medicine 2020;32(1):e23-
The ongoing coronavirus disease 2019 (COVID-19) pandemic is causing tremendous damage globally. The Republic of Korea (ROK), a highly export-dependent nation, is a leader in the fight against the COVID-19 pandemic and coping well with the disaster. Like the drivethrough COVID-19 testing, which reflects the brilliant flexibility of the Korean medical system, onsite mass workplace testing for COVID-19, which our hospital has been performing over the past few months, is a unique and valuable countermeasure. We believe it is time that the current health examination system for workers in the ROK considered the risk of transmissible diseases.
10.Update of aristolochic acid nephropathy in Korea.
Tae Hyun BAN ; Ji Won MIN ; Changhwan SEO ; Da Rae KIM ; Yu Ho LEE ; Byung Ha CHUNG ; Kyung Hwan JEONG ; Jae Wook LEE ; Beom Seok KIM ; Sang Ho LEE ; Bum Soon CHOI ; Jin Suk HAN ; Chul Woo YANG
The Korean Journal of Internal Medicine 2018;33(5):961-969
BACKGROUND/AIMS: The true incidence of aristolochic acid nephropathy (AAN) is thought to be underestimated because numerous ingredients known or suspected to contain aristolochic acid (AA) are used in traditional medicine in Korea. METHODS: We collected data on cases of AAN since 1996 via a database in Korea. We evaluated the year of AAN development, route to obtaining AA-containing herbal medicine, gender, reason for taking AA-containing herbal medicine, clinical manifestations, histological findings, phytochemical analysis, and prognosis of patients with AAN. RESULTS: Data on 16 cases of AAN were collected. Thirteen cases developed AAN before and three cases after the prohibition of AA-containing herbal medicine by the Korea Food and Drug Administration. Patients were prescribed AA-containing herbal medicine from oriental clinics or had purchased it from traditional markets. AAN was distributed in all age groups. Young females were most commonly exposed to AA-containing herbal medicine for slimming purposes and postpartum health promotion, while older adults took AA-containing compounds for the treatment of chronic diseases. The most common symptoms presented at hospitalization were nausea and vomiting, and acute kidney injury was accompanied by Fanconi syndrome in almost half of the patients. Phytochemical analysis of AA in herbal medicine was available in six cases. Progression to end stage renal disease (ESRD) was observed in seven patients (43.8%), and five patients (31.3%) had progressed to ESRD within 6 months of diagnosis. CONCLUSIONS: Our report shows that patients were still exposed to AA-containing herbal medicine and that there is a possibility of underdiagnosis of AAN in Korea. A stronger national supervision system of herbal ingredients and remedies in oriental medicine is needed to prevent AAN.
Acute Kidney Injury
;
Adult
;
Chronic Disease
;
Diagnosis
;
Fanconi Syndrome
;
Female
;
Health Promotion
;
Herbal Medicine
;
Hospitalization
;
Humans
;
Incidence
;
Kidney Failure, Chronic
;
Korea*
;
Medicine, East Asian Traditional
;
Medicine, Traditional
;
Nausea
;
Organization and Administration
;
Postpartum Period
;
Prognosis
;
United States Food and Drug Administration
;
Vomiting

Result Analysis
Print
Save
E-mail